Researchers are investigating the science behind the munchies, one of the best-known side effects of marijuana, in order to create a new medical treatment for eating disorders.
India Globalization Capital (IGC) has filed a patent for a new combination of cannabinoids and FDA-approved drugs intended to treat eating disorders like cachexia and anorexia. Cachexia is a condition in which a decrease in gastrointestinal function causes muscular weakness and a wasting away of the body. This disorder is often brought on by progressive illnesses like Parkinson's disease, cancer, HIV, and MS.
“Securing FDA approval for combination therapies is generally much faster and less expensive than the process for new drug applications,” Ram Mukunda, CEO of IGC said. “As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner.”
IGC is also seeking patents concerning new treatments for epilepsy. CBD is increasingly being accepted as an effective treatment for seizures in humans, and IGC is now researching medical marijuana as a treatment for pets with recurring seizures. Drugs like phenobarbital and potassium bromide are commonly prescribed to pets suffering from seizures, but these medications cause side effects including nausea, ataxia, and anxiety. Preclinical trials have showed that cannabis-derived treatments have been able to reduce these negative side effects.
